QuidelOrtho shares closed Wednesday’s session at $27.61, marking a decline of 2.27%. This downward movement occurred even as RBC Capital Markets issued a significant upgrade, raising its price target to $62 and reaffirming its “Outperform” rating on the stock.
Quarterly Results Present Contrasting Picture
Nearly a month after its Q2 earnings release, the company’s performance reveals a mixed financial landscape. QuidelOrtho posted adjusted earnings per share of $0.12, substantially surpassing the $0.01 consensus estimate. Revenue reached $614 million, also exceeding analyst projections.
However, a year-over-year comparison shows a 3.6% decrease in total revenue. This contraction was primarily driven by significant declines in COVID-19-related business and donor screening operations. The company reported a GAAP loss per share of $3.77, largely attributable to a $179 million restructuring charge connected to the discontinuation of its Savanna platform.
Operational metrics provided a brighter perspective. Adjusted EBITDA increased by 19% to $107 million, while the corresponding margin expanded by 330 basis points to reach 17%.
Should investors sell immediately? Or is it worth buying Quidelration?
Strategic Positioning and Market Outlook
The central question for investors remains whether QuidelOrtho can achieve sustainable profitability in a post-pandemic environment. The company’s Labs business demonstrated resilience with 4% growth, while non-COVID revenues showed minimal increases.
QuidelOrtho maintains a stable foundation with 96% of its revenue classified as recurring. The business maintains diversified revenue streams, with Labs contributing approximately 60% and Immunohematology accounting for 22% of total income.
Management reaffirmed its full-year guidance, projecting:
– Revenue: $2.6 to $2.81 billion
– Adjusted EBITDA: $575 to $615 million (representing a 22% margin)
– Adjusted EPS: $2.07 to $2.57
The investment community is anticipated to closely monitor the company’s third-quarter results, scheduled for release on November 6. While the average analyst price target of $42.17 suggests substantial potential upside, market sentiment currently reflects prevailing skepticism about near-term performance.
Ad
Quidelration Stock: Buy or Sell?! New Quidelration Analysis from February 7 delivers the answer:
The latest Quidelration figures speak for themselves: Urgent action needed for Quidelration investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.
Quidelration: Buy or sell? Read more here...
